“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of biosimilar products
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
The South African region has shown remarkable growth in pharmaceutical sales over the years. This is primarily attributed to the Government’s initiatives to improve healthcare access for its citizens as well as a favourable economic outlook across the market. The pharmaceutical market is valued at USD 3.9 billion and growing at 8% in value terms.
In FY2019, Lupin’s South African subsidiary Pharma Dynamics (PD) achieved net revenues of ZAR 1,162 million. According to IQVIA Health, as of March 2019, PD showed a sales growth of 5%. In addition, it has maintained its ranking as the 4th largest generics player in the prescription generic market in South Africa.
While PD has entrenched its position as the largest pharmaceutical company in the Cardiovascular Systems (CVS) therapeutic market, it is also growing in the Central Nervous System (CNS) space. The CVS portfolio remains the largest part of its revenues, followed by the OTC portfolio.
